Meeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 105 Authors: Luis G. Paz-Ares, Alexander Luft, Ali Tafreshi, et. al. Background: Pembro plus pemetrexed and carboplatin resulted in superior objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for untreated pts with non-sq NSCLC. Pembro is...
Pro zobrazení tohoto obsahu je třeba být přihlášen.